Daewoong’s Meropenem To Be First Korean Generic Launch In US
This article was originally published in PharmAsia News
Executive Summary
With an approval from the US FDA to sell its generic version of the carbapenem antibiotic meropenem, South Korea's Daewoong Pharma has taken a step further to achieving its long-term goal of transforming into a globally competitive pharma company by 2020.